New registry aims to unlock secrets of rare heart disease from gut tumors
NCT ID NCT07450287
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will create a registry of about 120 patients in Poland who have carcinoid heart disease, a rare complication of neuroendocrine tumors that damages heart valves. Researchers will collect medical records, echocardiograms, and lab results to better understand who develops this condition and how it is managed. The goal is to improve risk prediction and guide treatment decisions, such as when valve surgery or less invasive procedures are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors better identify who is at risk for severe heart valve problems from carcinoid tumors and guide better treatment choices.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. It may not lead to immediate changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID HEART DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institute of Cardiology in Warsaw
Warsaw, 04-628, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI ultrasound could unmask silent heart disease in seniors
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation